Brain Ischemia
Recent clinical, regulatory, research and industry developments relating to this disease.
Neuroinflammation in the Post-Ischemic Brain in the Presence of Amyloid and Tau Protein.
TRPM2 and CaMKII Signaling Drives Excessive GABAergic Synaptic Inhibition Following Ischemia.
Cardiovascular outcomes in breast cancer survivors: a systematic review and meta-analysis.
Migraine and cardiovascular disease: what cardiologists should know.
Stroke genetics informs drug discovery and risk prediction across ancestries.
Neuronal Death Mechanisms and Therapeutic Strategy in Ischemic Stroke.
What's happening now
An analyst briefing on current research, clinical, regulatory and industry activity surrounding this disease.
- 2 clinical trials with recent milestones (1 completed or reporting results).
Clinical MilestonesViewHide
- 2026-02-02ClinicalFUNCTIONAL ENDOSCOPIC NASAL AND SINUS SURGERY AND ANESTHESIA: Study of Hemodynamic Parameters During General Anesthesia Compared to the Surgical Field, as Well as Assessment of Cerebral Ischemia Intraoperatively by Measurement of S100B Protein and Specific Neuronal Enolase (NSE).Primary completion
- 2026-01-05ClinicalJapan Alteplase Clinical Trial (J-ACT): Phase 3 Efficacy and Safety Study of Tissue Plasminogen Activator (Alteplase) for Acute Ischemic Stroke Within 3 Hours of OnsetResults posted
Clinical trials
The current development programme across all trial phases.
Research activity
Key research shaping understanding of this disease, combining the latest publications with the most influential evidence.
Major themes8
- Brain Ischemia10
- Stroke7
- Ischemic Stroke4
- Alzheimer Disease2
- Cardiovascular Diseases2
- Reperfusion Injury2
- Adaptive Immunity1
- Amyloid1
Leading journals6
- The Journal of neuroscience : the official journal of the Society for Neuroscience6
- International journal of molecular sciences4
- The Journal of clinical investigation2
- The New England journal of medicine2
- Discovery medicine1
- European heart journal1
Leading researchers8
- Pluta R3
- Xu Y3
- Biernaskie J2
- Chen X2
- Chen Y2
- Corbett D2
- Li L2
- Markus HS2
Affiliations (unnormalised)6
- Department of Clinical Neurosciences3
- Medical University of Lublin3
- Affiliated Drum Tower Hospital2
- Memorial University of Newfoundland2
- School of Medicine2
- 60521 Ege University1
Disease biology
Key proteins & gene products studied in this disease. Number shows shared papers.
Related conditions
Diseases frequently studied alongside this one. Number shows shared papers.
Disease profile
A grounded synthesis of the condition — overview, causes, mechanism, risk factors and current standard of care.
Brain ischemia is a localized reduction of blood flow to brain tissue caused by arterial obstruction or systemic hypoperfusion. It often occurs together with brain hypoxia, and if prolonged it can progress to brain infarction and focal tissue death.
It is caused by arterial obstruction or systemic hypoperfusion. The literature grounding also describes ischemic stroke as resulting from occlusion of major cerebral arteries, small-vessel occlusion, atherosclerosis affecting the cerebral circulation, or embolism with a cardiac origin.
Reduced cerebral blood flow triggers ischemic injury that can lead to neuronal death, cerebral tissue death, and brain infarction. The grounding also supports roles for excitotoxicity, oxidative stress, inflammatory responses, neuroinflammation, blood-brain barrier disruption, cerebral edema, hemorrhagic transformation, and ischemia/reperfusion injury, with later phases contributing to tissue repair and functional recovery.
The supplied grounding supports systemic blood pressure as a factor influencing infarct size and neurological severity. It also supports vascular causes of ischemic stroke such as atherosclerosis, small-vessel disease, and cardiac embolism as contributors to risk, but does not provide a broader risk-factor list.
The grounding supports recanalization-based treatment, including intravenous alteplase and thrombectomy. It also indicates that therapeutic approaches have focused on targeting neuroinflammation and ischemia/reperfusion injury, but does not support more specific standard treatment categories beyond these modalities.
AI-generated summary grounded in MeSH and 6 peer-reviewed sources. Informational only — not medical advice. Generated 2026-07-07.
Reference
Authoritative identity, definition & identifiers.
Localized reduction of blood flow to brain tissue due to arterial obstruction or systemic hypoperfusion. This frequently occurs in conjunction with brain hypoxia (HYPOXIA, BRAIN). Prolonged ischemia is associated with BRAIN INFARCTION.
- Disease identity & definition — NLM Medical Subject Headings (MeSH), public domain
- Clinical trials — ClinicalTrials.gov (U.S. National Library of Medicine)
- Research activity — Europe PMC (EMBL-EBI) + OpenAlex-derived paper links
- Related entities are derived from literature co-mention (studied together) — associative, not causal.